Rethinking Alzheimer’s: From Protein Pathology to Early Risk Detection and Prevention

We have been looking at Alzheimer's from the wrong end.

For most of the last three decades, the dominant framework for understanding Alzheimer's disease has been built around two proteins: amyloid, which accumulates in plaques between neurons, and tau, which forms tangles inside them. As these proteins accumulate and the structures they disrupt begin to fail, the brain deteriorates and gradually, the person we knew disappears with it.

That framework has produced real science. It gave us better diagnostics, it shaped clinical trials and it eventually yielded the first drugs that appear to slow amyloid accumulation in early-stage disease. The research investment it has attracted is measured in the tens of billions of dollars and that investment was not misplaced.

But I think it has also, quietly and perhaps inevitably, narrowed the way we ask the question.

Because the more I study this disease and the more I observe what tends to precede it in the patients I see then  the more I find myself drawn back to a different question entirely. Not what destroys the brain once Alzheimer's is established, but what makes the brain vulnerable to that destruction in the first place. Not the end of the story, in other words, but the beginning of it.

The brain is an expensive organ.

It accounts for roughly two percent of body weight and consumes approximately twenty percent of the body's total energy, making it metabolically demanding in a way that almost nothing else in human biology is. It depends on continuous, efficient glucose utilisation and is acutely sensitive to insulin signalling, to vascular integrity, to mitochondrial function, to the quality of sleep and to the presence or absence of chronic low-grade inflammation. All of which makes it, when you think about it carefully, a remarkably fragile system for something we tend to assume will simply keep working.

Given all of that, one of the more consistent early findings in Alzheimer's research should probably surprise us less than it does. That finding is not necessarily massive amyloid accumulation. It is brain glucose hypometabolism. This is a measurable reduction in the brain's ability to utilise glucose efficiently. Detectable in vulnerable regions years, sometimes decades, before overt cognitive decline becomes apparent. The brain, in other words, is becoming energy-deficient long before anyone has made a diagnosis or even suspected one. It is struggling to fuel itself in silence and the conventional clinical encounter has almost no mechanism for detecting that.

That reality changes the conversation significantly.

Amyloid and tau still matter.

I want to be precise here because this is a point that is genuinely easy to misread, and I have no interest in overstating the case.

The amyloid and tau pathology in Alzheimer's disease is real, well-documented, and clinically significant. The research that identified it represents genuine scientific progress, and the drugs that target amyloid accumulation represent a meaningful step forward in a disease that has been extraordinarily resistant to treatment. None of that is in question.

But pathology and cause are not the same thing, and the distinction matters more than it might initially appear. What the emerging evidence increasingly suggests and this is where the more provocative question lives is that amyloid and tau may be part of a larger biological story rather than its beginning. That the brain may not simply be a passive victim of protein accumulation, but an organ that has first become vulnerable through metabolic dysfunction, impaired energy delivery, mitochondrial stress and a systemic inflammatory environment that has been building quietly for years before any protein pathology becomes detectable. In that reading, amyloid is not where the story starts. It may simply be where it becomes visible.

What drives that vulnerability?

The research is still developing, but the convergence of evidence points toward a set of factors that are not exotic or obscure; they are, in fact, the same factors that drive cardiovascular disease, metabolic syndrome and accelerated biological aging more broadly.

The first is insulin resistance. The brain is an insulin-sensitive organ and impaired insulin signalling disrupts glucose metabolism, promotes neuroinflammation and interferes with the clearance of amyloid from brain tissue. The relationship between type 2 diabetes and Alzheimer's risk is not coincidental rather it is mechanistic and some researchers have begun referring to Alzheimer's as type 3 diabetes, not as a formal diagnostic category but as a conceptual frame for understanding what sustained insulin dysregulation does to the brain over time.

The second is chronic low-grade inflammation. Neuroinflammation is both a well-established feature of Alzheimer's pathology and a plausible driver of it. Systemic inflammation, measurable through markers like hs-CRP and IL-6 crosses the blood-brain barrier, activates microglial cells and progressively degrades the neurological environment in which the brain's repair and clearance mechanisms operate. Over years, that degradation compounds.

The third is vascular health. The brain receives approximately twenty percent of cardiac output and anything that compromises the integrity of that delivery system compromises the brain's resilience. Sustained hypertension damages small cerebral vessels. Endothelial dysfunction reduces blood-brain barrier integrity. Poor cardiovascular fitness limits the cerebrovascular reserve that allows the brain to cope with demand. Every one of these factors reduces the brain's capacity to protect itself, and every one of them develops long before a cognitive test detects anything.

The fourth and perhaps the most underappreciated is sleep. During deep sleep, the glymphatic system, which functions as the brain's waste clearance infrastructure, becomes dramatically more active. Amyloid is cleared. Metabolic waste is removed and the internal environment is restored. Chronic poor sleep does not merely leave a person tired the following morning. It impairs, night after night, the biological housekeeping that keeps the brain environment clean enough to sustain healthy function across decades.

What makes this set of factors significant is not any single item within it. It is the recognition that every one of them is measurable, that most of them are modifiable and that none of them require a specialist to identify.

The window we keep missing.

The standard model of Alzheimer's care is organised around the point at which cognitive impairment becomes clinically obvious. The moment when the diagnosis is made, when treatment begins and when the family eventually starts to understand what is happening to the person they love. That is when medicine currently enters the story.

By that point, the underlying biology has in many cases been running for fifteen to twenty years.

I want to be clear that this is not a criticism of the clinicians who make those diagnoses. They are operating within a system that is structurally built to respond to symptoms rather than to track the biological conditions that eventually produce them, and working within those constraints as well as anyone could. The limitation is not clinical skill. It is architectural.

The window for meaningful intervention is not at the point of diagnosis. It exists during the period when the metabolic and inflammatory drivers of neurodegeneration are already active but the damage is not yet irreversible, which in many cases means years, possibly decades before any clinical presentation. During that period the biology is drifting in the wrong direction, the trajectory is still changeable, and the conventional healthcare encounter has almost no systematic reason to look. That window is currently almost entirely unmonitored in standard care. The biological drivers of Alzheimer’s are measurable long before symptoms appear. The question is whether they are being assessed.

What this means practically.

If the metabolic and vascular drivers of Alzheimer's are measurable long before cognitive decline appears, then the clinical tools we most need in this space are not primarily neurological. They are metabolic, inflammatory, and cardiovascular and they are tools that already exist.

Fasting insulin and HOMA-IR to assess insulin sensitivity. ApoB and Lp(a) to understand atherogenic burden. hs-CRP and other inflammatory markers to detect systemic inflammation before it becomes symptomatic. Blood pressure is tracked as a trajectory over years rather than a single reading at an annual appointment that may or may not reflect what is happening across the other three hundred and sixty-four days. Cardiorespiratory fitness is measured as VO2max, which is emerging as one of the strongest single predictors of long-term cognitive health in the literature. Sleep quality assessed in the context of its effect on glymphatic function. Biological age estimated through epigenetic clocks that can tell you not simply how old a person is, but how old their biology is behaving.

None of these are exotic investigations. None of them require a neurologist. All of them can be measured, tracked, and meaningfully acted on but only if the clinical environment is designed for longitudinal monitoring rather than episodic intervention and only if someone is paying attention to what the data shows over time rather than comparing a single result against a reference range and moving on.

That is the gap that preventive medicine exists to fill and it is a larger gap than most people appreciate.

The harder question.

Alzheimer's is forcing a confrontation that medicine has been able to defer in other disease areas, because in most of those areas the stakes of waiting are different.

In cardiovascular disease, we intervene aggressively once the diagnosis is established. Statins, antihypertensives, revascularisation procedures and the outcomes, while imperfect, are often genuinely meaningful. The disease responds to treatment. There is ground to recover.

In Alzheimer's, we cannot recover the ground once it is lost. The neurons are gone. The networks are disrupted. The person who was there has in important ways, already been lost before the diagnosis is officially made. That is not a counsel of despair but rather a biological reality and it is one that should force a fundamental rethinking of where medicine invests its attention not just in this disease but in the broader project of healthy aging.

Because what Alzheimer's makes viscerally clear is a principle that applies across nearly every chronic condition we face: the most important moment in the disease is not the moment of diagnosis. It is the long, silent period before it, when biology is drifting and the window for intervention is still genuinely open and when the conventional healthcare system has almost no systematic mechanism for being present.

I am not arguing that we should abandon the search for better treatments. We need them, and the progress being made is real.

What I am arguing is that we need to take the upstream question at least as seriously as the downstream one. And that argument, I think, carries a weight that goes beyond clinical practice.

We live in an era in which technology and data have fundamentally transformed how almost every other complex system manages risk. Aviation does not wait for an engine to fail before investigating why it might. Financial institutions model systemic vulnerability continuously, not after the crisis has already arrived. Engineering builds redundancy and monitoring into infrastructure precisely because waiting for failure is understood to be the most expensive strategy available. In each of these fields, the shift from reactive to proactive was not simply a technical upgrade. It was, I believe, a philosophical one, a decision about where in the timeline responsibility begins

Healthcare has not made that shift. Not because the knowledge is absent or because the tools are unavailable. The diagnostics exist, the biomarkers are validated and the clinical evidence for early intervention is strong and equally the science of modifiable risk in chronic disease is substantial and growing. We have built a system whose entire logic is organised around the moment of presentation and we have not seriously questioned whether that is the right moment to begin.

If we have the resources, the knowledge, and the tools to identify biological vulnerability years before it becomes disease, then the question of why we are not routinely doing so is no longer primarily a scientific one. It is an ethical one - a question about what medicine believes its responsibility actually is and at what point in a person's biological timeline that responsibility begins.

That question deserves a more honest answer than it has so far received. And the infrastructure to act on that answer, meaning clinical systems genuinely designed to monitor metabolic and inflammatory health longitudinally from midlife before any symptom has appeared, is not a future ambition. It is something we could be building now.

Alzheimer's is not an argument for pessimism. The science of modifiable risk is, if anything, genuinely encouraging. The factors that drive vulnerability are real, they are measurable, and in many cases they are changeable. But it is an argument for urgency, and for the willingness to ask the question at a different point in the biological timeline than we have been asking it.

Earlier. Much earlier than we currently do.

Explore a Preventive Health & Risk Assessment Consultation

Book consultation